Companies›Healthcare›Healthcare›Pharmaceuticals & Biotechnology

GOLDLINE PHARMACEUTICAL LIMITE

Healthcare › Pharmaceuticals & Biotechnology

₹32.98

at close · 27 Oct 2026

▲ 0.99 (+3.09%)

Get alerts

Latest filings

Mon, 12 OctReg 74(5) compliance filing for quarter ended September 30, 2026 · Compliance
Wed, 2 SeptPromoter buys 60,000 shares of Goldline Pharmaceutical via open market · Ownership Changes
Wed, 2 SeptPromoter Amol Mujumdar buys 18,000 shares of Goldline Pharma · Ownership Changes

All filings ↓

Ask Nexa about GOLDLINE PHARMACEUTICAL LIMITE

Snapshot

What the business is, and whether it's a good one at a fair price.

A Pharmaceuticals & Biotechnology company listed on BSE.

Market Cap

₹22 Cr

P / E (TTM)

—

EV / EBITDA

—

Div Yield

0.98%

Growth

—·

Revenue 5y CAGR

PAT — · EBITDA —

Quality

40.0%▲

ROCE (FY26)

ROE — · margin —

Leverage

—·

Debt / Equity · borrowings not filed

Moves on a normal day

2.30%·

Median daily move

Last 98 sessions · the yardstick for filing-day moves

Where it sits among 185 Pharmaceuticals peersBar = share of peers beaten · tick = industry median · latest reported figures

P/E (TTM)#17/158

ROCE#8/183

Scorecard

Measured from the filed financials, judged against its Pharmaceuticals peers · as of FY26 — not investment advice

Strengths

Returns on capital 40.0%

#8 of 183 in Pharmaceuticals on the latest reported figures

Concerns

Nothing flagged in the filed numbers.

Charts

How has the market priced it — with filings on the timeline?

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Peers

How does it stack up on valuation, returns and growth?

Loading peers…

Financials

Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.

Loading financials…

Ownership

Who owns it — and is the promoter stake clean?

Loading shareholding…

Governance

Is the board independent, clean and well-run?

Compliance

Did a company secretary sign off that it's clean?

Audit Report

What the auditor actually said — opinion, key audit matters, CARO clauses.

Earnings Call

What management said — and how it landed.

Investor Presentation

An AI read of the latest deck — verdict, KPIs, key slides and what it promised.

Events

Board meetings and results dates, upcoming and recent.

Reactions

How does the stock move after this company files?

Filings

The full disclosure feed.

Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.

Common questions

Answered from GOLDLINE PHARMACEUTICAL LIMITE's filed financials and exchange disclosures

What does GOLDLINE PHARMACEUTICAL LIMITE do?

GOLDLINE PHARMACEUTICAL LIMITE is a Pharmaceuticals & Biotechnology company listed on BSE.

Does GOLDLINE PHARMACEUTICAL LIMITE pay a dividend?

Yes. The dividend yield is 0.98% at the current price.

How much does the GOLDLINE PHARMACEUTICAL LIMITE share price move in a day?

On a typical session GOLDLINE PHARMACEUTICAL LIMITE moves 2.30% — that is the median absolute close-to-close move across its last 98 trading days. MarketPing measures each filing's price reaction against it.

Where can I track GOLDLINE PHARMACEUTICAL LIMITE's announcements?

Every NSE and BSE filing by GOLDLINE PHARMACEUTICAL LIMITE appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.

Figures are as last reported and may lag the latest filing. Not investment advice.